Biocal Kit150 mg+600 mg+400 IU

Biocal Kit is a combination bone-health product indicated for the following:

• Established/approved use: Treatment of postmenopausal osteoporosis, to reduce the risk of vertebral fractures.
• Established/approved use: Prevention of postmenopausal osteoporosis in women at increased risk of bone loss.
• Adjunct/supportive use: The algae-derived calcium and vitamin D3 components support adequate calcium and vitamin D intake, which is required alongside bisphosphonate therapy to maintain bone mineralization and reduce the risk of hypocalcemia.
• Guideline-supported use: As part of an overall osteoporosis management plan that also includes weight-bearing exercise, fall prevention, and lifestyle modification.

Biocal Kit is not indicated for the treatment of active hypercalcemia or for use in premenopausal osteoporosis unless specifically directed by a physician.

Ibandronic Acid + Algae Calcium + Vitamin D3 is a fixed combination product containing:

• Ibandronic Acid (as ibandronate sodium) - a nitrogen-containing bisphosphonate.
• Algae Calcium - a naturally derived calcium source obtained from marine algae (Lithothamnium calcareum), providing elemental calcium.
• Vitamin D3 (Cholecalciferol) - supports intestinal absorption of calcium and bone mineralization.

Exact strengths vary by brand and dosage form; refer to the specific product label for the quantity of each component.

Biocal Kit combines a bisphosphonate with algae-sourced calcium and vitamin D3 in a single product intended for the management of postmenopausal osteoporosis. Ibandronic acid works by slowing bone breakdown, while the calcium and vitamin D3 components help ensure that patients receive adequate substrate and cofactors for healthy bone formation during bisphosphonate treatment.

This combination approach is intended to simplify therapy by reducing the number of separate tablets a patient must take, while addressing both the anti-resorptive and mineral-supply aspects of osteoporosis management.

Biocal Kit belongs to the therapeutic class of bone resorption inhibitors (bisphosphonates) combined with calcium and vitamin D supplements. It is classified under anti-osteoporosis agents used for bone metabolism disorders.

Ibandronic Acid + Algae Calcium + Vitamin D3 has combined pharmacological actions from its three components:

Ibandronic Acid

Ibandronic acid is a nitrogen-containing bisphosphonate that binds strongly to bone hydroxyapatite and selectively inhibits osteoclast-mediated bone resorption, without directly affecting bone formation. This reduces the rate of bone turnover, leading to a net gain in bone mass and improved bone mineral density over time. It does not have direct effects on bone mineralization.

Algae Calcium

Algae-derived calcium supplies elemental calcium in a form that is absorbed via active and passive intestinal transport, providing the mineral substrate required for bone matrix mineralization.

Vitamin D3 (Cholecalciferol)

Vitamin D3 is hydroxylated in the liver and kidney to its active form, which increases intestinal absorption of calcium and phosphate and supports normal bone mineralization, working synergistically with the calcium component and offsetting the risk of hypocalcemia during bisphosphonate therapy.

Biocal Kit's bisphosphonate component must be taken on an empty stomach, first thing in the morning, with a full glass of plain water, followed by remaining upright for at least 60 minutes and avoiding food, drink, or other medicines during that period. The calcium/vitamin D3 component is generally taken with meals, at a different time from the bisphosphonate dose, to optimize absorption and avoid interaction. Do not lie down after taking the dose.

Clinically significant interactions with Biocal Kit include:

• Calcium, antacids, and mineral supplements (including the calcium content of this same product): Divalent cations such as calcium, magnesium, aluminum, and iron significantly reduce absorption of the ibandronic acid component if taken together. Doses of calcium/vitamin D3 and any other calcium-containing products must be separated from the ibandronic acid dose by at least 60 minutes.
• NSAIDs and aspirin: Concurrent use may increase the risk of gastrointestinal irritation; use with caution, particularly in patients with a history of GI disease.
• Other oral bisphosphonates or medications affecting calcium metabolism: Concomitant use is generally avoided as it does not add benefit and may increase risk of hypocalcemia or additive GI effects.

Side effects reported with Biocal Kit include:

• Common: Upper gastrointestinal discomfort (heartburn, dyspepsia, abdominal pain), musculoskeletal pain (back pain, myalgia, arthralgia), headache, and mild hypercalciuria or constipation related to the calcium component.
• Less common: Esophagitis, esophageal ulceration or erosion, flu-like symptoms (particularly after intravenous forms), dizziness, and rash.
• Rare but serious: Osteonecrosis of the jaw, atypical femoral fractures, severe esophageal reactions, and severe allergic reactions (angioedema, anaphylaxis).

Patients should report persistent chest pain, new or worsening heartburn, or difficulty/pain on swallowing immediately, as these may indicate esophageal irritation (see Precautions and Warnings).

Biocal Kit is generally not recommended during pregnancy. Bisphosphonates such as ibandronic acid are retained in bone for a prolonged period and released slowly over time, and their effects on the developing fetus are not well established; animal studies have shown reproductive toxicity at high doses. Biocal Kit should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus, and only under the direct supervision of a physician.

It is not known whether ibandronic acid is excreted in human breast milk. Because of the potential for serious adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Biocal Kit, taking into account the importance of the drug to the mother, in consultation with a physician.

The following precautions apply to Biocal Kit:

• Esophageal and upper GI irritation: Strict adherence to dosing instructions (upright posture, plain water, waiting period) is required to minimize the risk of esophagitis or esophageal ulceration; use with caution in patients with active upper GI problems.
• Osteonecrosis of the jaw (ONJ): A rare but serious risk associated with bisphosphonate therapy, more likely with invasive dental procedures. A dental examination is recommended before starting long-term therapy, and invasive dental work should be avoided during treatment where possible.
• Atypical femur fractures: Long-term bisphosphonate use has been associated with rare atypical subtrochanteric and femoral shaft fractures; patients should report new thigh or groin pain.
• Hypocalcemia: Correct pre-existing hypocalcemia and ensure adequate calcium/vitamin D intake (as supplied by this product) before and during therapy; monitor calcium levels in patients at risk (e.g., renal impairment, malabsorption).
• Renal impairment: Use with caution and appropriate dose adjustment in patients with mild-to-moderate renal impairment; avoid in severe renal impairment (see Contraindications).
• Vitamin D toxicity: Avoid additional high-dose vitamin D supplementation without medical advice, to prevent hypercalcemia from excess vitamin D intake.

Overdose of the ibandronic acid component may cause hypocalcemia, hypophosphatemia, and upper gastrointestinal irritation (esophagitis, gastritis, ulceration). Overdose of the calcium/vitamin D3 component may cause symptoms of hypercalcemia, including nausea, vomiting, constipation, confusion, and in severe cases, kidney impairment or arrhythmia.

In case of suspected overdose of Biocal Kit, seek immediate medical attention or contact a poison control center. Milk or antacids may be given to bind the drug if the oral bisphosphonate was recently ingested, but the patient should remain upright and be evaluated by a physician; do not attempt specific home treatment without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No overall dose adjustment is required based on age alone; renal function should be assessed, as elderly patients are more likely to have reduced renal function.

Renal impairment: Use with caution in mild-to-moderate impairment; avoid Biocal Kit in severe renal impairment (see Contraindications).

Hepatic impairment: No dose adjustment is generally required, as ibandronic acid is not metabolized by the liver; specific data are limited.

Pediatric patients: Not indicated; see Pediatric Uses.

Duration of treatment with Biocal Kit is determined by the treating physician based on bone mineral density response, fracture risk, and periodic reassessment, typically reviewed after 3-5 years of continuous bisphosphonate therapy to weigh the benefits of continued treatment against the rare long-term risks of atypical femur fracture and osteonecrosis of the jaw. The calcium/vitamin D3 component is generally continued as a supportive measure for as long as clinically indicated.

Bisphosphonate (bone resorption inhibitor) combined with calcium and vitamin D3 supplement; anti-osteoporosis agent.

The ibandronic acid component of Ibandronic Acid + Algae Calcium + Vitamin D3 binds to bone mineral (hydroxyapatite) at sites of active bone remodeling and is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway. This disrupts osteoclast cytoskeletal function and promotes osteoclast apoptosis, thereby suppressing bone resorption and increasing bone mineral density. The algae calcium and vitamin D3 components act synergistically by increasing intestinal calcium absorption and supplying the mineral substrate needed for bone mineralization, supporting the skeletal effects of reduced bone turnover.

Category C (bisphosphonate component; not recommended in pregnancy)

The safety and efficacy of Biocal Kit in pediatric patients have not been established. Biocal Kit is not indicated for use in children or adolescents, and bisphosphonates are generally avoided in this population outside of specialist-directed use in specific pediatric bone disorders. Use in pediatric patients should only occur under the direct supervision of a pediatric specialist for a clearly justified indication.